Endothelial P-Selectin as a Target of Heparin Action in Experimental Melanoma Lung Metastasis

Ralf J. Ludwig,¹ Beatrice Boehme,¹ Maurizio Podda,¹ Reinhard Henschler,¹ Elke Jager,³ Christa Tandi,¹ Wolf-Henning Boehncke,¹ Thomas M. Zollner,² Roland Kaufmann,¹ and Jens Gille¹,⁵

¹Department of Dermatology, Klinikum der J. W. Goethe-Universität, Frankfurt am Main; ²RBA Dermatology, Schering AG, Berlin; ³Department of Hematology/Oncology, Krankenhaus Nordwest, Frankfurt am Main; ⁴Institute of Transfusion Medicine, German Red Cross Blood Center, Frankfurt am Main; and ⁵Department of Molecular Biology, Max-Planck-Institut für Physiologische und Klinische Forschung, Bad Nauheim, Germany

ABSTRACT

Spontaneous and experimental metastasis can be effectively inhibited by the widely used anticoagulant heparin in different tumor models. At the cellular level, many of the antimetastatic effects of heparin in vivo are due to its action on P-selectin-mediated binding. Whereas previous attention has focused on P-selectin-dependent tumor-cell–platelet interactions in blood-borne metastasis, we sought to address the potential contribution of endothelial P-selectin expression to adhesive events between the microvasculature and melanoma cells in vitro. Transplantation of bone marrow from P-selectin-deficient into wild-type mice conveyed inhibition of experimental melanoma metastasis. However, the extent to which bone marrow-conferring lack of platelet P-selectin expression attenuated melanoma lung metastasis was significantly less than that seen in P-selectin-deficient mice, suggesting that endothelial P-selectin expression may additionally contribute to formation of hematogenous metastases. This assumption was supported by our intravital microscopy studies, in which a significant proportion of melanoma cells were capable of directly interacting with postcapillary venules of the murine ear in a P-selectin-dependent manner. Heparin not only inhibits P-selectin-mediated melanoma cell rolling but also attenuates melanoma metastasis formation in vivo, further supporting the concept that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.

INTRODUCTION

The formation of metastases depends on a series of events, including the arrest and extravasation of cancer cells in the capillary bed of secondary organs and the continued survival and initial proliferation after extravasation (1, 2). Most circulating cancer cells are thought to eventually arrest by mechanical factors, preferentially as a result of blood-flow pattern and size restriction.

Ample evidence supports the concept that blood-borne metastasis is significantly facilitated by interactions between disseminating tumor cells and blood platelets (3–5). Interference by antithrombotic agents or anticoagulants in tumor-cell–platelet association potently inhibits both spontaneous and experimental metastasis. In addition, measures that lower circulating platelet counts have resulted in a decrease in distant metastases. At the cellular level, tumor-cell–platelet interactions are assumed to both stabilize tumor cell arrest and assist cancer cell survival in secondary organs. In addition, platelet–tumor cell aggregates can protect from immune surveillance (6) and may supply tumor cells with critical stimulatory growth factors and cytokines, which are released on platelet activation (7, 8).

Important molecular mechanisms of tumor-cell–platelet interac-...
experimental lung metastasis. However, the extent to which BM-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was significantly less than that seen in P-selectin-deficient mice. Because we demonstrate that a significant fraction of melanoma cells directly interact with postcapillary venules in a P-selectin-dependent manner, endothelial P-selectin expression may additionally contribute to formation of hematogenous metastases. Heparin is shown to inhibit both P-selectin-mediated melanoma cell rolling and lung melanoma metastasis formation in vivo, providing further evidence that endothelial P-selectin expression may represent an extra target of heparin action in experimental melanoma lung metastasis.

MATERIALS AND METHODS

Mice. P-Selectin-deficient (P-sel−/−) mice on a C57BL/6J background (homozygous for the Selplf7/H11003 mutation) and control wt C57BL/6J mice were obtained from Charles River Deutschland GmbH (Sulzfeld, Germany) and were maintained on a 12-h light–dark cycle at the animal facility of the J. W. Goethe University. Mice were fed acidified drinking water and standard chow ad libitum. All protocols were approved by the governmental administration (Darmstadt, Hessen).

Cells and Culture Conditions. The human melanoma cell lines NW624 and NW1539 were generated and cultured as described previously (26). The murine melanoma cell line B16F10, originally derived from spontaneous melanoma of C57BL/6 origin, was from American Type Culture Collection (Rockville, MD). B16F10 cells were cultured at 37°C and 5% CO2 in DMEM (Gibco Invitrogen Corp., Karlsruhe, Germany) supplemented with 10% fetal calves, Deisenhofen, Germany). For intravital microscopy, cells were fluorescently labeled with 10 μM carboxyfluorescein diacetate, succinimidyl ester [CFDA-SE; Molecular Probes, Eugene, OR] or with 2.5 μM Vybrant DiI cell-labeling solution (Molecular Probes) for dual-color intravital microscopy according to the manufacturer’s instructions. For platelet isolation, blood was drawn from healthy volunteers through a 21-gauge needle. Blood was collected in 3-ml tubes containing sodium citrate (Sarstedt, Nümbrecht, Germany) and was centrifuged immediately at 110 × g for 15 min at 24°C to obtain platelet-rich plasma. Platelets were then separated from plasma proteins by gel filtration (27) through a Sepharose 2B column (Pharmacia, Uppsala, Sweden) followed by staining with phycoerythrin-labeled anti-CD41 (clone Ab; Pharmacia, Uppsala, Sweden) and FITC-labeled anti-CD62P-antibody (Ab; clone RB40.34; BD Biosciences) to identify platelets and P-selectin expression, respectively. Subsequently, cells were washed twice and analyzed by a BD FACScan Cytometer (Becton Dickinson, Mountain View, CA), equipped with CellQuest software for data acquisition and analysis (BD Biosciences). We collected 10,000 CD41+ cells for analysis of P-selectin expression.

Adherence of Platelets to Melanoma Cells. The adherence assay was performed according to the description by Kim et al. (29). Platelets were isolated as detailed above and were subsequently fluorescently labeled with 10 μM CFDA-SE. Before seeding, B16F10 cells were stained with 2.5 μM Vybrant DiI for dual-color fluorescence microscopy; B16F10 cells were grown to 50% confluency in 6-well plates overnight, washed with PBS, and incubated with TRAP-5-activated CFDA-SE-labeled platelets (3 × 105 cells/well) in the presence of blocking P-selectin Ab (5 μg/ml; clone WAPS12.2; Pierce Bio-technology, Rockford, IL) or isotype-matched control Ab (5 μg/ml; rat IgG1, clone 43414; R&D Systems, Wiesbaden, Germany) or in the presence of unfractionated sodium heparin (5 IU/ml). After shaking for 15 min at room temperature, wells were washed twice with PBS. CFDA-SE-labeled platelets and DiI-stained B16F10 cells were visualized by fluorescence microscopy of corresponding representative fields.

Intravital Microscopy. Intravital microscopy was performed as described previously (30, 31). In brief, mice were anesthetized by i.p. injection of ketamine (Ketamin; Schwabe-Curamed, Karlsruhe, Germany) and xylazine (Rompun; Bayer AG, Leverkusen, Germany) and were placed on a homothermic blanket. The right common carotid artery was prepared microsurgically, and a catheter was inserted for retrograde injection of cells and heparin. The left ear of the mouse was gently placed between a microscope slide and a coverslip. Vascular architecture and fluorescently labeled cells were visualized during their passage through vessels under fluorescent epi-illumination by either a Zeiss-09 filter system (Zeiss, Oberkochen, Germany) for single-color intravital microscopy or a multiband filter system (XF 53; Omega Optical, Brattleboro, VT) for two-color intravital microscopy. Continuous video recordings of the microcirculation were obtained from a 1/3-inch DSP-3 charge-coupled device camera (DXC-390; Sony, Cologne, Germany) mounted on a modified (32) Zeiss microscope (Axiovert 100 HD; Zeiss) equipped with a cooled charge-coupled device camera (DXC-390; Sony, Cologne, Germany) and DiI-stained B16F10 cells were visualized by fluorescence microscopy according to the manufacturer’s instructions. For platelet isolation, blood was drawn from healthy volunteers through a 21-gauge needle. Blood was collected in 3-ml tubes containing sodium citrate (Sarstedt, Nümbrecht, Germany) and was centrifuged immediately at 110 × g for 15 min at 24°C to obtain platelet-rich plasma. Platelets were then separated from plasma proteins by gel filtration (27) through a Sepharose 2B column (Pharmacia, Uppsala, Sweden) and activated by the thrombin receptor-activating peptide TRAP-5 at 2.5 mm (Bachem, Heidelberg, Germany). Human peripheral blood mononuclear cells were prepared by Ficoll-Paque PLUS density gradient sedimentation (American Diagnostics, Germany), stained with 2.5 μM Vybrant DiI cell-labeling solution (Molecular Probes), and adjusted to 3 × 107 cell/ml in AIM V cell culture medium (Gibco).

Experimental Lung Metastasis Assay. To prepare B16F10 cells for inoculation, cells were harvested by brief exposure to a 0.25% trypsin–EDTA solution (Sigma). Cell viability in single-cell suspensions was determined by trypan blue exclusion. A total of 3 × 105 B16F10 cells (>90% viability) in 100 μl of PBS were injected into the lateral tail vein of 8–12-week-old male syngeneic C57BL/6J mice (Charles River). As indicated, selected mice received commercially available unfractionated sodium heparin [12.5 or 60 IU (100 μl) in 0.9% sodium chloride; Liquemin; Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany] 30 min before inoculation or every second day starting 24 h after tail vein injection. Animals were sacrificed 11 days postinjection, and lungs were excised and fixed in phosphate-buffered 10% formaldehyde. Metastatic foci at lung surfaces were counted by two observers in a blinded fashion.

Murine BM Transplantation Model. BM cells were obtained by flushing the femurs of donor P-selectin-deficient mice in C57BL/6J background (Charles River) as described previously (28). Recipient C57BL/6J mice received lethal irradiation doses at 4–6 weeks of age, and animals received i.v. injections containing 2–3 × 106 BM cells. BM cells from normal C57BL/6J mice were taken as controls. At 6 weeks post-transplantation, by which time the BM of recipient mice was reconstituted, melanoma cell inoculation was performed.

Analysis of P-Selectin Expression. When mice were sacrificed at day 11 postinjection for analysis of lung metastases, blood was obtained by heart puncture and anticoagulated with sodium citrate (Sarstedt). Five μl of blood were immediately diluted in 50 μl of PBS containing calcium and magnesium. Platelets were activated with epinephrine (Aventis, Bad Soden, Germany) followed by staining with phycoerythrin-labeled anti-CD41 (clone MWRreg30; BD Biosciences, Heidelberg, Germany) and FITC-labeled anti-CD62P-antibody (Ab; clone RB40.34; BD Biosciences) to identify platelets and P-selectin expression, respectively. Subsequently, cells were washed twice and analyzed by a BD FACScan Cytometer (Becton Dickinson, Mountain View, CA), equipped with CellQuest software for data acquisition and analysis (BD Biosciences). We collected 10,000 CD41+ cells for analysis of P-selectin expression.

RESULTS

Transplantation of BM from P-Selectin-Deficient Mice Attenuates Lung B16F10 Melanoma Metastasis. Previously, the development of experimental lung metastasis after i.v. injection of colon carcinoma cells has been demonstrated to be significantly diminished in P-selectin-deficient mice (12, 13). To determine whether P-selectin deficiency also affected syngeneic B16F10 melanoma lung metastasis, we analyzed lung colony formation in P-selectin-deficient mice compared with wt controls (Fig. 1A). We found that the number of metastatic foci at lung surfaces was significantly reduced in P-selectin-deficient mice (median, 48 versus 246 in wt controls), supporting the assumption that a critical role of P-selectin for lung colonization is not restricted to particular subsets of tumor cells.

At present, primarily P-selectin expression by platelets has been implicated in assisting the process of metastasis via tumor-cell-
platelet interactions (7). Comparable to previous findings on LS-180 colon cancer cells (29), activated platelets adhered to murine B16F10 melanoma cells in a P-selectin-dependent fashion (Fig. 2). In a manner similar to the effect seen with blocking P-selection Ab (Fig. 2B), the presence of heparin almost entirely suppressed adherence of platelets to B16F10 cells (Fig. 2C). To provide further evidence for the significance of P-selectin expression by platelets, we transplanted BM from P-selectin-deficient into wt mice to explore whether the lack of platelet P-selectin expression would convey inhibition of experimental lung metastasis. BM from either wt mice [wt BM transplantation (BMT)] or from P-selectin-deficient mice (P-sel−/− BMT) was transplanted in lethally irradiated wt recipient C57BL/6J mice (Fig. 1B). To confirm BM reconstitution, peripheral blood from each animal was analyzed for P-selectin expression on platelet activation (Fig. 1, D and E). Analyses of colonies at lung surfaces 11 days after injection of B16F10 cells revealed significant attenuation of met-
observed in both wt BMT /H9251 and P-selectin antibody (versus median, 138 static foci in mice that received BM from P-selectin-deficient mice). These experiments revealed that a highly reproducible proportion of different melanoma cell lines interacted with tumor cells and murine endothelium of postcapillary venules (Fig. 3). These analyses revealed that the extent to which the BM-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was significantly lower than that seen in P-selectin-deficient mice (Fig. 1C). These analyses revealed that the extent to which the BM-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was further decreased by anti-P-selectin Ab. We thus hypothesized that endothelial P-selectin-expressing cells may additionally assist formation of hematogenous metastases.

**P-Selectin-Dependent Melanoma Cell-Endothelial Cell Interactions in Vivo Are Blocked by Heparin Treatment.** To further assess the potential role of endothelial P-selectin in melanoma metastases, we performed intravital microscopy experiments, which permitted direct analyses of interactions between injected tumor cells and murine endothelium of postcapillary venules in vivo (Fig. 3). These experiments revealed that a highly reproducible proportion of different melanoma cell lines interacted with skin microvessels (Fig. 3, A, E, and F; Table 1). The proportion of interacting tumor cells seemed not to be affected by P-selectin expression by circulating platelets; proportions of rolling melanoma cells in P-sel−/−/BMT chimeric mice were equivalent to those observed in both wt BMT and in wt mice (Fig. 3, C and D). Melanoma cell rolling was diminished by blockade of mouse static foci in mice that received BM from P-selectin-deficient mice (median, 138 versus 228 in wt BMT controls). These data substantiate the current view that P-selectin expression by platelets represents an important factor of blood-borne metastasis. However, the extent to which the BM-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was significantly lower than that seen in P-selectin-deficient mice (Fig. 1, A and B). These data suggest that P-selectin expression by cells other than platelets may contribute to metastasis of experimental melanoma. This interpretation is also supported by our experiments in which the effects of an anti-P-selectin Ab on lung metastasis formation were tested in mice that received P-selectin-deficient BM (Fig. 1C). These analyses revealed that the extent to which the BM-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was further decreased by anti-P-selectin Ab. We thus hypothesized that endothelial P-selectin expression may additionally assist formation of hematogenous metastases.

**P-Selectin-Mediated Melanoma Rolling Is Targeted by Heparin**

![Image](cancerres.aacrjournals.org)
P-selectin binding (monoclonal Ab RB40.34; BD Biosciences; Fig. 3D). Adhesive interactions were also sensitive to heparin, which is known to act as a potent P-selectin inhibitor (23, 24). On the other hand, diminished rolling in P-selectin-deficient mice was not further reduced by heparin treatment (Fig. 3, A and B), further supporting the interpretation that tumor cells contacted murine ear postcapillary venules primarily in a P-selectin-dependent fashion. Observed differences of cell velocities were not due to changes in blood flow (Table 1).

Because we recently observed that activated platelets can form aggregates with leukocytes in vivo, resulting in increased rolling of leukocytes along vascular endothelium of the murine ear in a P-selectin-dependent fashion (33), we aimed to determine whether melanoma–endothelial cell interactions would be enhanced in the presence of activated platelets in a comparable manner. To discriminate between melanoma cells and platelets, we used two-color intravital microscopy. Activated platelets were stained with the green fluorescent dye CFDA-SE, and NW1539 cells were fluorescently vital microscopy. Activated platelets were stained with the green fluorescent dye CFDA-SE, and NW1539 cells were fluorescently stained. These experiments revealed neither considerable platelet–tumor cell interactions in vivo nor increased melanoma cell rolling in postcapillary venules of the murine ear (Fig. 4). Therefore, in contrast to platelet-mediated leukocyte delivery to skin endothelium, NW1539 melanoma cell adhesive interactions with endothelium may not be assisted by activated platelets.

**Heparin Inhibits Experimental Melanoma Metastasis only if Administered before B16 Melanoma Cell Inoculation.** Various independent studies have revealed that blood-borne metastasis can be effectively attenuated by the anticoagulant heparin in different tumor models (19). Our results confirmed these previous findings (13, 34): a single dose of unfractionated sodium heparin before tumor challenge resulted in a dose-dependent reduction of experimental B16F10 melanoma metastasis (Fig. 5). Significant inhibition by heparin was already observed at a dose of 12.5 IU, with further reduction seen at 60 IU. To address whether heparin may additionally affect formation and growth of lung colonies after melanoma challenge, metastatic foci at lung surfaces were additionally assessed in mice that had been treated only after melanoma inoculation or in which heparin was administered both before and after tumor challenge. Initiation of heparin treatment 24 h after melanoma challenge had no effect on blood-borne metastasis (Fig. 4). Correspondingly, intermittent injection of heparin every second day after tumor cell inoculation failed to induce additional or synergistic antimetastatic effects compared with mice treated before tumor challenge only. Heparin thus appears to mainly interfere with the establishment of metastasis rather than the initiation or maintenance of metastatic tumor growth.

**DISCUSSION**

Accumulating evidence indicates that many of the in vivo anti-metastatic effects of heparin reflect its action on P-selectin-mediated binding (10, 29). Whereas previous attention has focused mainly on P-selectin-dependent cell–platelet interactions as important determinants of blood-borne metastasis, the potential contribution of endothelial P-selectin expression to adhesive events between the microvasculature and tumor cells has yet to be elucidated. Several cell surface glycoconjugates bearing selectin-binding sites have previously been detected in melanoma cells. Lewis antigens (e.g., sialyl Lewis X and sialyl Lewis a; Refs. 35, 36) and heparin sulfate-like proteoglycans have been identified as potential P-selectin ligand determinants (16). The interaction of tumor cell glycoconjugates with P-selectin expressed by platelets and endothelial cells may therefore facilitate extravasation and survival of circulating melanoma cells (12). Significantly, in the present study we showed that transplantation of BM from P-selectin-deficient mice conveys inhibition of experimental lung metastasis, further establishing the dependence of metastasis formation on P-selectin expression. At the same time, these experiments revealed that P-selectin-dependent attenuation of lung metastasis in deficient mice can be explained only in part by the lack of platelet P-selectin expression (Fig. 1). Therefore, these results suggested to us that P-selectin expression by endothelial cells may also be involved in enhancing the metastatic efficiency of melanoma cells.

Earlier studies on hematogenous metastasis have indicated that circulating tumor cells generally arrest in the microcirculation of secondary organs and may extravasate with high efficiency (37), regardless of the tumor type or the metastatic ability. Experimental in vivo observations and histological analyses revealed that the majority of cancer cells usually arrest in the first capillary bed because of size restrictions (38, 39). Despite efficient arrest and initial extravasation, however, significant differences are present relating to the subsequent propensity of cancer cells to survive extravasation and to proliferate to form metastatic colonies (1). We...
inhibitor (23, 24). On the other hand, diminished rolling in P-selectin-deficient mice was sensitive to heparin, which is known to act as a potent P-selectin antagonist in greater detail (7, 19). Different heparin preparations were shown to act as ligands for P-selectin, thereby blocking binding of monocytes or neutrophils (18). In the context of leukocyte extravasation, P-selectin-dependent binding. This assumption is also supported by recent findings, we have recently observed that activated platelets can induce signal transduction pathways that convey changes in gene expression and cytoskeletal arrangement, thereby affecting cellular survival and proliferation of single tumor cells during extravasation (37).

Whereas the inhibitory effects of heparin on experimentally induced metastasis have been repeatedly reported in distinct models over past years, the cellular and molecular mechanisms by which heparin mediates its actions have only recently been elucidated in greater detail (7, 19). Different heparin preparations were shown to act as ligands for P-selectin, thereby blocking binding of P-selectin to its natural and tumor mucin ligands (23, 24). Importantly, both tumor-cell–platelet aggregation and experimental metastasis of human carcinoma cells were seen to be significantly inhibited in P-selectin-deficient mice (29). In an equivalent fashion, we found that lung colonization of syngeneic B16 melanoma cells was markedly attenuated in P-selectin-deficient mice compared with wt controls (Fig. 1). Because L-selectin expression by leukocytes may also facilitate metastatic spread in vivo (10), the inhibitory effects of heparin on L-selectin binding may additionally convey the antimetastatic effects observed in our studies. However, both experimental lung metastasis formation (Fig. 5) and melanoma cell rolling (Fig. 3) are attenuated by heparin treatment to an extent comparable to that seen in P-selectin-deficient mice (Fig. 1), suggesting that the heparin effects detected in our experimental models are mediated primarily by inhibition of P-selectin-dependent binding. This assumption is also supported by recent studies on colon carcinoma cell metastasis that indicated that the effect of a single heparin dose is accounted for by blockade of P-selectin function only (10). Heparin not only impaired P-selectin-dependent platelet–tumor cell interactions but also suppressed blood-borne metastasis in secondary organs, whereas in P-selectin-deficient mice no further inhibition by heparin treatment was seen (10, 13). Therefore, substantial evidence supports the concept that heparin mediates its antimetastatic effects to a great extent via inhibition of P-selectin-dependent interactions.

Activated platelets have been shown previously to facilitate leukocyte–endothelial cell interactions in a P-selectin-dependent fashion, providing an additional mechanism for leukocyte delivery to the microvasculature (42, 43). Evidence has been provided that leukocyte–platelet interactions may augment both direct adhesion of blood mononuclear cells to the endothelium (44) and indirect leukocyte adhesion via bridging platelets (42). Pertinent to these findings, we have recently observed that activated platelets can form aggregates with leukocytes in vivo, resulting in increased rolling of leukocytes along vascular endothelium of the murine ear in a P-selectin-dependent fashion (33). We hypothesized that melanoma–endothelial cell interactions would be enhanced in the presence of activated platelets in a comparable manner. Use of a two-color intravital microscopy that allows for discrimination between melanoma cells and platelets in vivo revealed neither considerable platelet–tumor cell interactions nor increased melanoma cell rolling in postcapillary venules of the murine ear (Fig. 4). Therefore, in contrast to platelet-mediated leukocyte delivery to skin endothelium, melanoma cell adhesive interactions with endothelium may not be assisted by activated platelets.

Strikingly, a single dose of unfractionated heparin resulted in significant reduction of experimental blood-borne metastasis (13,
P-SELECTIN-MEDIATED MELANOMA ROLLING IS TARGETED BY HEPARIN

34). Previous studies have also indicated that both unfractionated and different fractionated heparin preparations may exert antimetastatic effects in a dose-dependent fashion (34). However, the extent to which heparin may additionally affect formation and growth of lung colonies after tumor challenge has yet to be resolved. Sciumbata et al. (34) reported a slight but insignificant prolongation of survival when heparin treatment was maintained on a twice/week cycle for 3 weeks after i.v. injection of B16 melanoma cells. The results from our heparin treatment studies clearly suggest that initiation of heparin treatment 24 h after tumor challenge has no effect on blood-borne metastasis (Fig. 4). Similarly, continued injection of heparin every second day after melanoma cell inoculation failed to produce additional or synergistic antimetastatic effects compared with mice treated before tumor challenge only. Thus, heparin seems to primarily interfere with the establishment of metastases rather than the initiation or maintenance of metastatic tumor growth.

Heparin comprises a complex set of glycosaminoglycan molecules that, in addition to the established anticoagulant effects, have been shown to modulate numerous cellular functions (19). Because inhibition of P-selectin represents a key mechanism by which heparin mediates its antimetastatic as well as its anti-inflammatory properties, specific oligosaccharide structures in heparin have been identified recently that may specifically interact with P-selectin (25). These studies indicated that inhibitory properties depend on 6-O-sulfated glucosamine residues, which are distinct from the binding site for antithrombin that confers the potent anticoagulant activity of heparin (45). Hence, chemically modified heparins are conceivable that exert diminished anticoagulant activity but retain antimetastatic properties. Alternatively, noncarboxylic imidazole-based selectin inhibitors, which have been identified by use of a P-selectin ELISA-based assay system, may characterize an attractive class of compounds with potential therapeutic effects on metastasis formation (46). In addition, we have recently shown that efomycines, comprising a novel family of small molecules with inhibitory effects on selectin-dependent cell binding, exhibit considerable efficacy in different disease models of cutaneous inflammation (30). Hence, it will be of utmost interest to investigate whether these compounds will actually interfere with P-selectin-dependent tumor cell rolling and metastasis formation in vivo.

We here provide evidence that endothelial P-selectin expression may contribute to the formation of hematogenous metastases. This assumption is supported by transplantation studies with BM from P-selectin-deficient mice, revealing that P-selectin-dependent attenuation of lung metastasis in deficient mice can be explained only in part by the lack of platelet P-selectin expression. In addition, we demonstrated that melanoma cells directly interact with postcapillary venules in a P-selectin-dependent manner, an interaction that can be fully abrogated by heparin treatment. These results thus indicate that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.

ACKNOWLEDGMENTS

We gratefully acknowledge the excellent technical assistance of S. Diehl, J. E. Schultz, and M. Stein.

REFERENCES

Endothelial P-Selectin as a Target of Heparin Action in Experimental Melanoma Lung Metastasis

Ralf J. Ludwig, Beatrice Boehme, Maurizio Podda, et al.


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/64/8/2743

Cited articles  This article cites 41 articles, 18 of which you can access for free at: http://cancerres.aacrjournals.org/content/64/8/2743.full.html#ref-list-1

Citing articles  This article has been cited by 24 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/64/8/2743.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.